- Avadel Pharmaceuticals press release (NASDAQ:AVDL): Q3 GAAP EPS of -$0.33 misses by $0.07.
- Cash, cash equivalents and marketable securities were $106.5 million as of September 30, 2022.
- Also, as of September 30, 2022, the Company had $26.4 million of convertible debt that matures in February 2023 and $117.4 million that matures in October 2023.